

ALEXION PHARMACEUTICALS INC
 Form 3
 October 08, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Wagner Heidi L (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 10/01/2015	3. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) SVP, Global Government Affairs	5. If Amendment, Date Original Filed(Month/Day/Year)
--	--	---	--	--

C/O ALEXION PHARMACEUTICALS, INC,Â 352 KNOTTER DRIVE
 (Street)

CHESHIRE,Â CTÂ 06410
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$.0001 per share	25,916	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Option to Purchase Common Stock	05/02/2011	02/02/2021	Common Stock, par value \$0.0001 per share	9,500	\$ 42.655	D	Â
Option to Purchase Common Stock	05/03/2012	02/03/2022	Common Stock, par value \$0.0001 per share	14,000	\$ 78.88	D	Â
Option to Purchase Common Stock	02/12/2013	11/12/2022	Common Stock, par value \$0.0001 per share	3,000	\$ 91.98	D	Â
Option to Purchase Common Stock	05/06/2013	02/06/2023	Common Stock, par value \$0.0001 per share	18,807	\$ 93.83	D	Â
Option to Purchase Common Stock	02/28/2015	02/28/2024	Common Stock, par value \$0.0001 per share	20,000	\$ 176.8	D	Â
Option to Purchase Common Stock	02/27/2016	02/27/2025	Common Stock, par value \$0.0001 per share	15,000	\$ 180.37	D	Â
Option to Purchase Common Stock	10/01/2016	10/01/2025	Common Stock, par value \$0.0001 per share	5,000	\$ 157.82	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wagner Heidi L C/O ALEXION PHARMACEUTICALS, INC	Â	Â	Â SVP, Global Government Affairs	Â

352 KNOTTER DRIVE
CHESHIRE, CT 06410

Signatures

/s/ Michael V. Greco, Attorney-in-fact for Heidi L.
Wagner

10/08/2015

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.